The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
 
Christian K. Kollmannsberger
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer; Sanofi
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - Novartis; Novartis; Novartis
Consulting or Advisory Role - Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Novartis; Novartis; Novartis
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; G1 Therapeutics; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); Immune Design (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)
 
James Christensen
Employment - Mirati Therapeutics; Pfizer
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Mirati Therapeutics; Pfizer
 
Vanessa Roberts Tassell
Employment - Aragon Pharmaceuticals; Mirati Therapeutics
Stock and Other Ownership Interests - Aragon Pharmaceuticals; Mirati Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Aragon Pharmaceuticals
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Demiana Faltaos
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst)